Innovation
Bringing innovation to patients, better and faster
We're harnessing the power of advanced tech, combined with our deep understanding of the science of the immune system, to develop new medicines and vaccines.
Investors
We announced our full year and fourth quarter 2025 results on Wednesday, 4 February.
Press releases
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSK Global links
Visit our Global site for additional features









